| Expression pattern: |
UP |
| Associated gene: |
VCAN |
| Associated microRNA: |
hsa-miR-6512-3p, hsa-miR-6720-5p |
| Biological function: |
Promotes gastric cancer progression and contributes to an immunosuppressive tumor microenvironment. |
| Molecular mechanism: |
ceRNA mechanism by sponging miRNAs (hsa-miR-6512-3p and hsa-miR-6720-5p) to regulate VCAN within a hub circRNA/miRNA/mRNA axis linked to immune microenvironment changes. |
| Biological pathway or process: |
EMT (promotes); NF-kappaB (promotes); angiogenesis (promotes); TGF-beta/SMAD (other); JAK/STAT (other); Notch (other); inflammation (other) |
| Detected method: |
M
|
| Validation methods: |
Microarray; Bioinformatics Analysis |
| Clinical significance: |
Significantly correlated to the clinical outcomes (via the novel regulatory axis). |
| Description: |
hsa_circ_0061695 (also referred to as circRNA DYRK1A_017) is upregulated in gastric cancer and is proposed as part of a hub ceRNA axis with miR-6512-3p/miR-6720-5p and VCAN. This axis is linked to pro-tumor pathways (e.g., EMT, TNFalpha-NFkappaB signaling, angiogenesis) and an immunosuppressive tumor microenvironment. |
| Confidence score: |
0.1768 |